Slide 1: Investor and Analyst Conference Call FY 2019
INVESTOR AND ANALYST CONFERENCE CALL FY 2019 Grünwald, 8 April 2020
Slide 2: Disclaimer
Disclaimer This publication includes statements, estimates, opinions and projections with respect to the anticipated future performance of Dermapharm Holding SE (together with its consolidated subsidiaries, “Dermapharm”) and such statements, estimates, opinions and projections (“Forward- Looking Sta
Slide 3: Agenda
AGENDA 1. Highlights FY 2019 2. Financial figures FY 2019 3. Outlook FY 2020 4. Q & A
Slide 4: Agenda: Highlights FY 2019
AGENDA 1. Highlights FY 2019 2. Financial figures FY 2019 3. Outlook FY 2020 4. Q & A
Slide 5: Financial highlights FY 2019
Financial highlights FY 2019 Guidance was met in the best possible way Guidance 2019 FY 2019 results Revenues ++ 14% to + 19% + 22.4% vs. previous year (€572.4m) (€700.9m) EBITDA(1) + 17% to + 22% + 23.8% (adjusted) vs. previous year (€143.4m) (€177.6m) Note: (1) EBITDA FY 2019 adjusted for non-recu
Slide 6: Operational highlights FY 2019
Operational highlights FY 2019 Continuous consequent implementation of Dermapharm`s three-pillar-strategy Pipeline of more than 50 ongoing development projects(1) on track; Inhouse development successful launches of self-developed products in different countries Regional expansion through founding o
Slide 7: Market and Legal highlights FY 2019
Market and Legal highlights FY 2019 Changes in market and legal situation Increase in sales despite competition, slight increase in self-payer Dekristol® 20.000 share, participation in SHI(1) tenders to secure SHI market Warning of the drug authorities of an increased "skin cancer risk" when HCT - A
Slide 8: Investment highlights FY 2019
Investment highlights FY 2019 Expansion of logistic and production capacities to secure Dermapharm`s future growth New central group logistic hub additional 12,000 m2 of usable space 3,500 picking places 3,500 pallet spaces for replenishment New production site 6,000 m2 of usable space pro
Slide 9: Latest News – Events after the reporting period
Latest News – Events after the reporting period +++ Corona crisis +++ latest M&A +++ change in board +++ Influence in its entirety is not predictable; the pharmaceutical Corona virus industry also offers positive aspects. Allergopharma – German specialist in therapeutics for Latest acquisition desen
Slide 10: Agenda: Financial figures FY 2019
AGENDA 1. Highlights FY 2019 2. Financial figures FY 2019 3. Outlook FY 2020 4. Q & A
Slide 11: Dermapharm Group
Dermapharm Group Strong overall growth driven by branded pharmaceuticals Total Revenue (€m) EBITDA(2) (€m, adjusted) Comments EBITDA margin +22.4% YoY 25.1% 25.3% 700.9 Significant revenue growth of 22.4% to €700.9m, due to organic growth in all segments 572.4(1) overall intact 3-pillar-strategy
Slide 12: Branded pharmaceuticals and other healthcare products
Branded pharmaceuticals and other healthcare products Growth expansion continues Revenue (€m) EBITDA(2) (€m, adjusted) Comments EBITDA Margin 40.8% 41.2% Revenues up by 15.1% to €385.1m largely based on organic growth supplemented by self-developed products Dekristol® 20.000 increased in sales
Slide 13: Parallel import business
Parallel import business Despite rising sales, margins declined due to challenging market environment Revenue (€m) EBITDA (€m) Comments EBITDA Margin 3.8% 3.4% +2.4% YoY Revenues increased slightly by 2.4% to €243.5m continued demand for parallel imported originator products stable legal import
Slide 14: Herbal extracts (new segment since 01/2019)
Herbal extracts (new segment since 01/2019) Results are within managements expectations Revenue (€m) EBITDA(1) (€m, adjusted) Comments EBITDA Margin 22.7% Revenues of this new segment developed according to plan with €72.3m 72.3 comprising Euromed constantly growing worldwide demand for herbal e
Slide 15: Earnings before tax (Group EBT)
Earnings before tax (Group EBT) Result diluted by strong M&A activities Earnings before tax (EBT)(1) (€m) Comments EBT Margin 18.2% 15.7% EBT increased by 5.7% to €110.1m (unadjusted) resulting in a lower margin of 15.7% +5.7% YoY Mainly influenced by 110.1 increasing depreciation and amortisati
Slide 16: Strong Cash flows and cash conversion
Strong Cash flows and cash conversion Reflecting strong dedication to future growth Cash flow and cash conversion(1)(€m) Comments in % of Group EBITDA Cash conversion 110.9% 56.9% CF from operating activities mainly influenced by settlement of receivables from Themis Beteiligungs-AG in the first
Slide 17: Balance sheet of Dermapharm Group
Balance sheet of Dermapharm Group Balance Sheet as of 31 December 2019 (€m) Comments Total assets increased to €1,045m (31 December 2018: €705m) Non-current assets increased to €692m 1,045 1,045 (31 December 2018: €333m), mainly due to increase in intangible assets, goodwill and property, plan
Slide 18: Agenda: Outlook FY 2020
AGENDA 1. Highlights FY 2019 2. Financial figures FY 2019 3. Outlook FY 2020 4. Q & A
Slide 19: Dividend proposal
Dividend proposal Dividend proposal and next Annual General Meeting: Due to positive business development and solid financial basis, Dividend proposal the Management Board is proposing a dividend of € 0.80 per share AGM Next Annual General Meeting: Munich – 17 June 2020 19
Slide 20: Growth strategy on track and informing guidance 2020
Growth strategy on track and informing guidance 2020 positive growth in the upper Revenues 2020 single-digit percentage range vs. previous year (€700.9m) positive growth in the upper EBITDA 2020 (adjusted) single-digit percentage range vs. previous year (€177.6m) Growth rates are based on organic gr
Slide 21: Agenda: Q & A
AGENDA 1. Highlights FY 2019 2. Financial figures FY 2019 3. Outlook FY 2020 4. Q & A
Slide 22: Investor contact
Investor contact Britta Hamberger Investor Relations & Corporate Communications Dermapharm Holding SE E-Mail: ir@dermapharm.com Phone: +49 (0) 89 641 86 233